AVITA Medical, Inc. (AVH.AX)
| Previous close | 3.8700 |
| Open | 3.9300 |
| Bid | 4.0400 x 734600 |
| Ask | 4.0500 x 258500 |
| Day's range | 3.9300 - 4.1700 |
| 52-week range | 1.8800 - 6.2700 |
| Volume | |
| Avg. volume | 235,600 |
| Market cap | 517.4M |
| Beta (5Y monthly) | 1.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.03 |
GlobeNewswireAVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on December 5, 2023, at 2:00 p.m. (PS
- GlobeNewswire
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time. A live webcast of the present
- GlobeNewswire
AVITA Medical Updates Full Year 2023 Guidance
VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced an update to its full year 2023 guidance. This update is a result of slower-than-anticipated progression through the customer’s Value Analysis Committee (VAC) processes, driven by the expanded label application
